“Widespread Adoption of Connected Health Devices and Insulin Delivery Innovations”
- A significant and accelerating trend in the global insulin market is the growing integration of insulin therapies with connected health devices, including continuous glucose monitors (CGMs), insulin pumps, and mobile health applications. This technological convergence is enabling more accurate, personalized, and data-driven diabetes management for patients
- For instance, the Tandem t:slim X2 insulin pump, when integrated with Dexcom CGMs, enables automated insulin delivery adjustments based on real-time glucose readings. This closed-loop functionality, often referred to as an “artificial pancreas,” enhances glycemic control and reduces the burden on patients
- In addition, companies such as Medtronic have developed smart insulin delivery systems that use predictive algorithms to minimize hypoglycemic episodes by automatically suspending insulin delivery when low glucose levels are anticipated
- The rising popularity of mobile applications designed for insulin tracking and dose calculation, such as mySugr and Glooko, is also contributing to the modernization of diabetes care. These apps sync with wearable devices to log glucose levels, carbohydrate intake, and physical activity, helping both patients and healthcare providers make informed decisions
- Pharmaceutical leaders including Eli Lilly and Novo Nordisk are actively developing connected insulin pens that record dosage data and transmit it to mobile apps, supporting real-time monitoring and improved treatment adherence. For instance, NovoPen 6 and NovoPen Echo Plus are already gaining traction in Europe and North America
- This shift towards integrated digital solutions is transforming traditional insulin delivery into a holistic, tech-enabled experience, driving demand across both advanced and emerging healthcare systems. As a result, healthcare providers are increasingly embracing these innovations to improve patient outcomes and streamline diabetes management
